Document Detail


Using OKT3 to reverse cardiac allograft rejection.
MedLine Citation:
PMID:  2506149     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Acute rejection is the major impediment to long-term patient survival after organ transplantation. Historically, the treatment of cardiac allograft rejection has been use of cytotoxic agents combined with high-dose steroids, resulting in an increased incidence of undesirable side effects. A new agent, OKT3, appears to be capable of reversing acute rejection episodes without significant morbidity. We report 10 cardiac transplant recipients in whom acute rejection was dramatically reversed and clinical symptoms resolved after treatment with OKT3. Side effects were minimal, including febrile episodes, innocuous diarrheal syndromes, mild opportunistic infections, and one hypotensive episode. Critical care nurses administering OKT3 must be cognizant of the risks and benefits of therapy in addition to recognizing potential drug side effects. A nursing care plan was devised to identify nursing diagnoses and intervention related to patient and family education as well as recognition and treatment of the reported adverse effects.
Authors:
K R Rogers; J T Sinnott; J E Ferguson
Related Documents :
11054419 - A non-peptide functional antagonist of the ccr1 chemokine receptor is effective in rat ...
8971889 - Risk factors for chronic rejection in pediatric renal allograft recipients.
6400729 - Acute vascular rejection treated by plasma exchange.
8821839 - Chronic renal allograft rejection: immunologic and nonimmunologic risk factors.
22571389 - Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of th...
6990559 - Differentiation between irreversible and reversible rejection in renal transplant patie...
15648439 - Enhancement of rat islet tolerance with bone marrow transplantation using a non-myeloab...
2572849 - Detection of residual bcr/abl translocation by polymerase chain reaction in chronic mye...
17574919 - Bone marrow cell-mediated cardiovascular repair: potential of combined therapies.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Heart & lung : the journal of critical care     Volume:  18     ISSN:  0147-9563     ISO Abbreviation:  Heart Lung     Publication Date:  1989 Sep 
Date Detail:
Created Date:  1989-10-25     Completed Date:  1989-10-25     Revised Date:  2006-08-28    
Medline Journal Info:
Nlm Unique ID:  0330057     Medline TA:  Heart Lung     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  490-6     Citation Subset:  AIM; IM    
Affiliation:
Cardiac Transplant Services, Tampa General Hospital, FL 33601.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adolescent
Adult
Antibodies, Monoclonal / adverse effects,  therapeutic use*
Female
Graft Rejection*
Heart Transplantation*
Humans
Male
Middle Aged
Muromonab-CD3
Nursing Care
Nursing Diagnosis
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Muromonab-CD3

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of radiometric and microbiological assays for the determination of folate in fortified gr...
Next Document:  Success of mutant Drosophila at different sex ratios.